Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector

Molecular Therapy

Volumn 5, Issue 1, 2002, Pages 63-73

  Reddy, P Seshidhar ^a   Sakhuja, Kiran ^a   Ganesh, Shanthi ^a   Yang, Lijuan ^a   Kayda, Dawn ^a   Brann, Terrence ^a   Pattison, Scott ^a   Golightly, Doug ^a   Idamakanti, Neeraja ^a   Pinkstaff, Anne ^a   Kaloss, Michele ^a   Barjot, Catherine ^b   Chamberlain, Jeffrey S ^b   Kaleko, Michael ^a   Connelly, Sheila ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Factor VIII; Gene therapy; Gutless vector; Hemophilia

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8; CAPSID PROTEIN; LIVER ENZYME; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; ENZYME BLOOD LEVEL; FEMALE; GENE CASSETTE; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC CODE; HELPER VIRUS; HEMOPHILIA A; HUMAN; HUMAN CELL; LIVER TOXICITY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ASSAY; SENSITIVITY ANALYSIS; VIRAL CONTAMINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0036154968     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0510     Document Type: Article

References (49)

1. High-level tissue-specific expression of functional human factor VIII in mice
2. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy
3. In vivo evaluation of an adenoviral vectorecoding canine factor VIII: High-level, sustained expression in hemophiliac mice
4. Complete short-term correction of canine hemophilia A by in vivo gene therapy
5. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs
6. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates
7. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII
8. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
9. Sustained expression of therapeutic levels of human factor VIII in mice
10. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors
11. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo
12. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: Requirement for E4 ORF3
13. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products
14. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII
15. High-capacity adenoviral vectors for gene transfer and somatic gene therapy
16. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
17. Optimization of the helper-dependent adenovirus system for production and potency in vivo
18. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector
19. Construction of adenovirus vectors through Cre-lox recombination
20. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging
21. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
22. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
23. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity
24. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
25. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells
26. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
27. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion
28. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy
29. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase
30. Replication and recombination in adenovirus-infected cells are temporally and functionally related
31. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
32. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus
33. Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors
34. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
35. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo
36. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors
37. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
38. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo
39. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
40. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype
41. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
42. Stable transduction of actively dividing cells via a novel adenoviral/episomal vector
43. Stabilization of transgenes delivered by recombinant adenovirus vectors through extrachromosomal replication
44. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy
45. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
46. Adenovirus vectors for gene therapy
47. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
48. In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice